Professor Seong-beom Lee graduated from the College of Medicine at the Catholic University of Korea in 1991 and obtained his board certification as a specialist in Surgical Pathology in 1996. He worked as a researcher at the Department of Life Sciences at POSTECH from 1996 to 1999 and received his Ph.D. from the Graduate School of the Catholic University of Korea in 2000. Afterward, he served as a researcher at the Department of Biology at the University of Notre Dame in the United States from 2003 to 2005. He has been working at the Department of Pathology at the Catholic University of Korea College of Medicine since 1996. Professor Lee's main research interests focus on the cell invasion mechanism and  the mechanism of phagosome maturation inhibition of Mycobacterium leprae, the causative agent of Hansen's disease. Additionally, Professor Lee provides mobile medical services for patients with Hansen's disease. He was awarded the "Teacher of the Year" award in Korea in 2013.

Professor Younggwang Kim earned his M.D. from Yonsei University College of Medicine and became a board-certified neurologist. He received his M.S. degree for research on Parkinson’s disease and Parkinson’s disease dementia, and later obtained his Ph.D. for his studies on genome editing and high-throughput genetic screening.

From 2021 to 2023, he served as a research assistant professor in the Department of Pharmacology at Yonsei University College of Medicine, and in 2023, he joined the Department of Pathology at the Catholic University College of Medicine.

Professor Kim has conducted large-scale functional screening of tumor-associated genetic alterations using CRISPR-based genetic libraries, and published these findings twice in leading scientific journals, including Nature Biotechnology. In recognition of his research achievements, he received the 2025 Boehringer Ingelheim–Korean Academy of Medical Sciences (KAMS) Wunsch Medical Award Young Medical Scientist Award.

His laboratory focuses on developing novel gene therapies for intractable genetic diseases using gene-editing technologies such as CRISPR-Cas9. The team also investigates the genetic variants underlying human diseases, discovers new gene correction platforms, and identifies key regulators that can enhance the efficacy of cell-based therapies through library-based high-throughput screening. These studies are conducted in close collaboration with multiple clinical departments, including Neurology, Rheumatology, and Neurosurgery, to translate basic research findings into clinically applicable therapeutic strategies.